GlobeNewswire Inc.··NaIchnos Glenmark Unveils First-in-Class Cancer Immunotherapy ISB 2301 Targeting Solid Tumors
Ichnos Glenmark Innovation announced ISB 2301, a first-in-class multispecific antibody targeting solid tumors via dual immune activation. IND submission planned for end of 2026.
ABBVclinical developmentsolid tumors